Tuesday, 13 May 2025
  
Login

Australia's most trusted
source of pharma news

Tuesday, 13 May 2025
News

Tuberculosis drug finally approved

Posted 12 May 2024 AM

The TGA waved through a handful of medicines last week, including AFT Pharmaceuticals' tuberculosis treatment and the first generic version of GSK’s nasal spray Avamys.

AFT Pharmaceuticals' Pyrazinamide-AFT, which was accepted for review in September 2023 - roughly 20 months ago - is an anti-tuberculosis agent used in combination with other anti- tuberculosis agents and is commonly used in the first two months of treatment. It has been approved for patients of more than 12 years of age with active drug-sensitive tuberculosis caused by Mycobacterium tuberculosis. 

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (12)

Clinical & Medical, R&D (5)

Regulatory, Pharmacovigilance & QA (4)

Other (14)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.